Dechra adds new seborrhoeic dermatitis treatment to dermatology portfolio

Dechra adds new seborrhoeic dermatitis treatment to dermatology portfolio

09 January 2019

A new, symptomatic treatment to tackle seborrhoeic dermatitis in cats and dogs has been unveiled by Dechra Veterinary Products.

Dermanolon®, which is available in a practical 75 ml spray bottle, combines triamcinolone acetonide and salicylic acid to effectively target lesions in hard to access spots. It is a useful alternative for animals when shampooing is not possible.

The easy to administer treatment does not contain an antibiotic therefore does not contribute to antimicrobial resistance.

Triamcinolone acetonide, a moderately potent steroid with an anti-inflammatory and vasoconstrictive action, suppresses the inflammatory response and the symptoms of various disorders often associated with itching.

Salicylic acid gives a keratolytic effect and also removes excess skin cells when applied cutaneously and provides a drying effect, which prevents maceration.

Dechra Brand Manager Carol Morgan said: “Seborrhoeic dermatitis is associated with a higher skin pH compared to that of healthy dogs so Dermanolon’s low pH of approximately 2.7 reduces the pH of the skin following application giving an antibacterial and antimycotic effect.

“It also contains ethanol that prevents the build-up of a greasy film on the skin and has bactericidal properties.”

Carol added: “Seborrhoeic dermatitis can be a debilitating condition for animals and a challenge to treat effectively. Adding Dermanolon to our portfolio offers veterinary professionals another valuable tool for the care and treatment of animals with dermatological diseases.”

For more information on Dechra’s dermatology range, go to